While several tumor types expressing PRAME have established standard-of-care treatments, including checkpoint inhibition in melanoma [39], chemotherapy, and targeted therapy (such as EGFR pathway inhibition and beyond) in lung cancer [40], clinical benefit from such therapies can be transient, with tumors evolving drug resistance, resulting in continued unmet need. The gene discussed is EGFR; the disease is neoplasm.